Peculiarities of Manifestation of Paranoid Delusions in the World
DOI:
https://doi.org/10.47451/psy2025-08-01Keywords:
pathological condition, delusion, psychiatry, mental disorder, schizophreniaAbstract
The relevance of the investigated problem lies in several debatable issues that the psychiatric community is trying to solve, one of which is the definition of clear clinical criteria for paranoid delusions. Long-term studies of disorders of thinking, perception, will, motor activity, which cause the formation of false conclusions about the surrounding world, today do not provide a comprehensive answer to the causes of the distorted consciousness of an individual. The purpose of the study is the diagnosis and research of the limits of the manifestation of paranoid delusions, which develops in the context of a personality disorder. The main method used to study the features of the manifestation of paranoid delusions was the clinical-psychopathic method. To conduct it, psychometric methods, psycho-diagnostic methods, as well as clinical and statistical methods of data processing were used as an auxiliary research tool. During this empirical study of the patient’s personality, his intelligence, and cognitive abilities, it was possible to achieve results according to which the main criteria of a personality with manifestations of paranoid delusions were determined. Therefore, the main results of the study are the determination of the general regularity of the combination of mental and behavioural disorders, as a result of which a change in the clinical picture of the disease is observed. The general level of perception of the quality of life of patients with paranoid delusions was determined; a reasonably high level of suicidal risk; the reasons for the low level of social interaction in the professional and family spheres are revealed; identified determinants that increase depressive symptoms; the main behavioural strategies used by patients to interact with the surrounding people in the environment are presented. The practical significance of the materials of the article lies in the further successful correction of borderline states of mental illnesses in psychotherapy; in organizational psychiatric treatment; prevention and rehabilitation of mental pathologies.
Downloads
References
Borozenets, A., Dumchev, K., Zlydenny, T., Ivanchuk, I., Kabanchyk, M., Kolomiets, V., & Pinchuk, I. (2020). Mental and behavioral disorders (addiction syndrome) as a result of opioid use. Clinical guideline. Public Health Alliance, 5(3), 25–28.
Casarella, J. (2020). Delusions and Delusional Disorder. WebMD Editorial Contributors. https://www.webmd.com/schizophrenia/guide/delusional-disorder
Cosgrave, J., Purple, R. J., & Haines, R. (2021). Do environmental risk factors for the development of psychosis distribute differently across dimensionally assessed psychotic experiences? Translational Psychiatry, 11(20), 226–231.
Craske, M., Meuret, A., & Ritz, T. (2019). Positive affect treatment for depression and anxiety: A randomized clinical trial for a core feature of anhedonia. Journal of Consulting and Clinical Psychology, 87(5), 457–471.
Deisenhammer, F., Zetterberg, H., & Fitzner, B. (2019). The cerebrospinal fluid in multiple sclerosis. Frontiers in Immunology, 10(33), 89–96.
Fedorchuk, S., Іvaskevych, D., Borysova, O., Коhut, O., Маrynych, V., Тukaiev, S., & Petrushevskyi, I. (2020). Coping strategies in connection with psychophysiological characteristics of skilled female handball players. Bulletin of National University of Physical Education and Sport of Ukraine, 2(8), 315–322.
Gannon, J., Brar, J., Rai, A., & Chengappa, K. (2019). Effects of a standardized extract of Withania somnifera (Ashwagandha) on depression and anxiety symptoms in persons with schizophrenia participating in a randomized, placebo-controlled clinical trial. Annals of Clinical Psychiatry, 31(2), 123–129.
Hinojosa-Marqués, L., Monsonet, M., Kwapil, T. R., & Barrantes-Vidal, N. (2021). The impact of family environment on self-esteem and symptoms in early psychosis. Maastricht. PLoS ONE, 16(4), 49–72.
International Classification of Diseases 11th revision. (2022). World Health Organization. https://icd.who.int/en
Kalin, N. (2021). Depression and Schizophrenia: Sleep, Medical Risk Factors, Biomarkers and Treatment. American Journal of Psychiatry, 178(10), 881–884.
Mikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021). HPA axis in the pathomechanism of depression and schizophrenia: new therapeutic strategies based on its participation. Brain Sciences, 11(10), 1298.
Musliner, K., Mortensen, P., & McGrath, J. (2019). Association of polygenic liabilities for major depression, bipolar disorder, and schizophrenia with risk for depression in the Danish population. JAMA Psychiatry, 76(5), 516–525.
Napreyenko, O. (2019). Schizophrenia: causes, features of manifestation and treatment. Psychiatry, 2(3), 10–19.
Pugle, M. (2021). What Is Paranoia? Very Well Health. https://www.verywellhealth.com/paranoia-5113652
Safai, Y. (2022). Paranoia and schizophrenia: What you need to know. Medical News Today, 5(3), 37–43.
Sall, J., Brenner, L., & Millikan, B. (2019). Assessment and Management of Patients at Risk for Suicide: Synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines. Annals of Internal Medicine, 171(5), 343–353.
Stavytska, S., Sydorenko, O., Stavytskyi, G., Otych, D., & Fedorenko, A. (2021). Methodological recommendations for conducting educational psychodiagnostic practice for students of specialty 053 “Psychology”, educational degree “Bachelor”. Kyiv: Department of the NPU named after M.P. Drahomanova.
Syropyatov, O., Dzerzhunska, N., Drevitska, O., Gorshkov, O., Butska L., Mazhbits, V., & Marushchenko, K. (2021). Organizational and medico-psychological measures to prevent suicidal behavior in the army. International Scientific Journal “Grail of Science”, 2(3), 516–525.
Tibber, M., Kirkbride, J., & Mutsatsa, S. (2019). Are socioenvironmental factors associated with psychotic symptoms in people with first-episode psychosis? A cross-sectional study of a West London clinical sample. BMJ, 10(11), 30–44.
Zhyvaho, Kh. (2021). The use of psychotropic drugs in the complex of measures of medical and social rehabilitation of patients with paranoid form of schizophrenia with depressive symptoms. Psychological Health, 1(6), 92–101.
Zimmerman, M. (2021). Paranoid personality disorder (PPD). Medical Review, 5(6), 12–19.
Published
Issue
Section
License
Copyright (c) 2025 European Scientific e-Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
The European Scientific e-Journal (ESEJ) is an open access journal. Articles are available free of charge as PDF files on the website of the European Institute for Innovation Development. PDF files can be previewed with Acrobat Reader from www.adobe.com.
All articles of the “Tuculart Student Scientific” are published under a Creative Commons Attribution 4.0 Generic (CC BY 4.0) International license.
According to the Creative Commons Attribution 4.0 Generic (CC BY 4.0) International license, the users are free to Share — copy and redistribute the material in any medium or format for any purpose, even commercially (the licensor cannot revoke these freedoms as long as you follow the license terms).
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
